Paramount BioSciences

Halozyme taps Labarre as chief scientific officer

Monday, August 31, 2015

Halozyme Therapeutics, a San Diego-based biotechnology company developing novel oncology and drug-delivery therapies, has named Michael J. LaBarre, Ph.D., as chief scientific officer, succeeding Dr. Michael Shepard, who was appointed a Research Fellow for the company. The move broadens LaBarre’s responsibilities to include R&D of early pipeline assets, in addition to his role managing product development and ENHANZE platform partnerships.

[Read More]